BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16602111)

  • 1. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
    J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
    BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
    Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
    Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
    Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid: an unending tale for an antiresorptive agent.
    Caraglia M; Marra M; Naviglio S; Botti G; Addeo R; Abbruzzese A
    Expert Opin Pharmacother; 2010 Jan; 11(1):141-54. PubMed ID: 20001436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
    Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
    Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
    Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation.
    Yamada J; Tsuno NH; Kitayama J; Tsuchiya T; Yoneyama S; Asakage M; Okaji Y; Shuno Y; Nishikawa T; Tanaka J; Takahashi K; Nagawa H
    J Surg Res; 2009 Jan; 151(1):115-20. PubMed ID: 18619615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
    Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
    Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
    Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
    Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
    Ory B; Heymann MF; Kamijo A; Gouin F; Heymann D; Redini F
    Cancer; 2005 Dec; 104(11):2522-9. PubMed ID: 16270320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
    Mitrofan LM; Pelkonen J; Mönkkönen J
    Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells.
    Tenta R; Sourla A; Lembessis P; Koutsilieris M
    Anticancer Res; 2006; 26(1A):283-91. PubMed ID: 16475708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
    Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
    Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
    Koto K; Horie N; Kimura S; Murata H; Sakabe T; Matsui T; Watanabe M; Adachi S; Maekawa T; Fushiki S; Kubo T
    Cancer Lett; 2009 Feb; 274(2):271-8. PubMed ID: 18986762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
    Moriceau G; Ory B; Mitrofan L; Riganti C; Blanchard F; Brion R; Charrier C; Battaglia S; Pilet P; Denis MG; Shultz LD; Mönkkönen J; Rédini F; Heymann D
    Cancer Res; 2010 Dec; 70(24):10329-39. PubMed ID: 20971812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells.
    Chen YJ; Chao KS; Yang YC; Hsu ML; Lin CP; Chen YY
    Immunopharmacol Immunotoxicol; 2009; 31(3):499-508. PubMed ID: 19555208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
    Koizumi M; Nakaseko C; Ohwada C; Takeuchi M; Ozawa S; Shimizu N; Cho R; Nishimura M; Saito Y
    Eur J Haematol; 2007 Nov; 79(5):382-91. PubMed ID: 17903213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.